Cidara Therapeutics, Inc. (CDTX)

NASDAQ: CDTX · IEX Real-Time Price · USD
0.712
+0.005 (0.66%)
At close: Mar 1, 2024, 4:00 PM
0.708
-0.005 (-0.66%)
After-hours: Mar 1, 2024, 7:47 PM EST
0.66%
Market Cap 64.41M
Revenue (ttm) 56.54M
Net Income (ttm) -31.37M
Shares Out 90.43M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE 5.75
Dividend n/a
Ex-Dividend Date n/a
Volume 238,423
Open 0.712
Previous Close 0.708
Day's Range 0.704 - 0.739
52-Week Range 0.593 - 2.100
Beta 0.93
Analysts Strong Buy
Price Target 4.67 (+555.72%)
Earnings Date Mar 21, 2024

About CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 15, 2015
Employees 73
Stock Exchange NASDAQ
Ticker Symbol CDTX
Full Company Profile

Financial Performance

In 2022, CDTX's revenue was $64.29 million, an increase of 29.69% compared to the previous year's $49.57 million. Losses were -$29.80 million, -29.83% less than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CDTX stock is "Strong Buy." The 12-month stock price forecast is $4.67, which is an increase of 555.72% from the latest price.

Price Target
$4.67
(555.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO

SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunothera...

20 days ago - GlobeNewsWire

Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapies designed to save lives and improve the standard of care for patients...

4 weeks ago - GlobeNewsWire

Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults

SAN DIEGO, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced REZZAYO (rezafungin acetate) has been approved in the European Union (EU) for the treatment of inv...

2 months ago - GlobeNewsWire

Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

First in class, multi-specific CD73/PD-1 inhibitor DFC, exhibited robust anti-tumor activity in humanized mouse models of colorectal cancer at low doses

3 months ago - GlobeNewsWire

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology developing therapies designed to save lives and improve the standard of care for patients facing ...

3 months ago - GlobeNewsWire

Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID

PARSIPPANY, N.J. & SAN DIEGO--(BUSINESS WIRE)--Melinta Therapeutics, LLC and Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced the peer-reviewed publication of pooled data from two completed gl...

3 months ago - Business Wire

Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time

3 months ago - GlobeNewsWire

Cidara Therapeutics Named as a San Diego Metro Area Top Workplace

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunothera...

3 months ago - GlobeNewsWire

Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC's 38ᵗʰ Annual Meeting

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunothera...

4 months ago - GlobeNewsWire

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard ...

4 months ago - GlobeNewsWire

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)

SAN DIEGO and CAMBRIDGE, England, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conju...

5 months ago - GlobeNewsWire

Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1

CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--Mundipharma and Cidara Therapeutics (Nasdaq: CDTX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Huma...

5 months ago - Business Wire

Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapies d...

5 months ago - GlobeNewsWire

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) --  Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunothe...

5 months ago - GlobeNewsWire

Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023

SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunother...

5 months ago - GlobeNewsWire

Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023

• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza from Janssen Pharmaceuticals, Inc. leadership following Election to Proceed notification

6 months ago - GlobeNewsWire

Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunother...

6 months ago - GlobeNewsWire

Cidara Therapeutics Announces Janssen's Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza

Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials Cidara to receive a $7 million milestone payment and is eligible to receive an additional $685 million in...

6 months ago - GlobeNewsWire

Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development

Dr. Davarpanah will lead Cidara's oncology efforts, focusing on strategy to advance development candidates Previously served as Clinical and Translational Lead in Oncology at Genentech/Roche SAN DIEGO...

7 months ago - GlobeNewsWire

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing immunotherapeutics designed to help improve the standard of care for patients ...

7 months ago - GlobeNewsWire

Cidara Therapeutics Provides Update on REZZAYO™ (rezafungin for injection)

Cidara's U.S. Commercial Partner, Melinta Therapeutics, has Initiated Commercial Launch of REZZAYO™ EMA Regulatory Decision for Rezafungin Expected by Year End 2023 SAN DIEGO, July 31, 2023 (GLOBE NEW...

7 months ago - GlobeNewsWire

Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for pat...

8 months ago - GlobeNewsWire

Cidara Therapeutics Added to Russell Microcap® Index

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of ca...

8 months ago - GlobeNewsWire

Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of ca...

9 months ago - GlobeNewsWire

Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit

SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for pat...

9 months ago - GlobeNewsWire